<DOC>
	<DOCNO>NCT00224536</DOCNO>
	<brief_summary>After successful percutaneous coronary intervention ( PCI ) acute ST-segment elevation myocardial infarction , 60 patient randomly assign either control group ( n=30 ) receive optimum postinfarction medical treatment , bone-marrow-cell group ( n=30 ) receive optimum medical treatment intracoronary transfer autologous bone-marrow cell 4·8 day ( SD 1·3 ) PCI . Primary endpoint global left-ventricular ejection fraction ( LVEF ) change baseline 6 month ’ follow-up , determined cardiac MRI . Image analyse do two investigator blind treatment assignment . Analysis per protocol . Global LVEF baseline ( determined 3·5 day [ SD 1·5 ] PCI ) 51·3 ( 9·3 % ) control 50·0 ( 10·0 % ) bone-marrow cell group ( p=0·59 ) . After 6 month , mean global LVEF increase 0·7 percentage point control group 6·7 percentage point bone-marrow-cell group ( P=0·0026 ) . Transfer bone-marrow cell enhance left-ventricular systolic function primarily myocardial segment adjacent infarcted area . Cell transfer increase risk adverse clinical event , in-stent restenosis , proarrhythmic effect .</brief_summary>
	<brief_title>Bone Marrow Transfer Enhance ST-Elevation Infarct Regeneration</brief_title>
	<detailed_description>Emerging evidence suggest stem cell progenitor cell derive bone marrow use improve cardiac function patient acute myocardial infarction . In randomised trial , aim ass whether intracoronary transfer autologous bone-marrow cell could improve global left-ventricular ejection fraction ( LVEF ) 6 month ’ follow-up . After successful percutaneous coronary intervention ( PCI ) acute ST-segment elevation myocardial infarction , 60 patient randomly assign either control group ( n=30 ) receive optimum postinfarction medical treatment , bone-marrow-cell group ( n=30 ) receive optimum medical treatment intracoronary transfer autologous bone-marrow cell 4·8 day ( SD 1·3 ) PCI . Primary endpoint global left-ventricular ejection fraction ( LVEF ) change baseline 6 month ’ follow-up , determined cardiac MRI . Image analyse do two investigator blind treatment assignment . Analysis per protocol . Global LVEF baseline ( determined 3·5 day [ SD 1·5 ] PCI ) 51·3 ( 9·3 % ) control 50·0 ( 10·0 % ) bone-marrow cell group ( p=0·59 ) . After 6 month , mean global LVEF increase 0·7 percentage point control group 6·7 percentage point bone-marrow-cell group ( P=0·0026 ) . Transfer bone-marrow cell enhance left-ventricular systolic function primarily myocardial segment adjacent infarcted area . Cell transfer increase risk adverse clinical event , in-stent restenosis , proarrhythmic effect . Intracoronary transfer autologous bone-marrow-cells promotes improvement left-ventricular systolic function patient acute myocardial infarction .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients eligible admit within 5 day onset symptom first STsegment elevation myocardial infarction Had undergone successful PCI stent implantation infarctrelated artery Had hypokinesia akinesia involve two third leftventricular anteroseptal , lateral , and/or inferior wall , show angiography do immediately PCI . We exclude patient multivessel coronary artery disease , pulmonary edema , cardiogenic shock , advance renal hepatic dysfunction , document terminal illness cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Bone marrow cell</keyword>
	<keyword>Intracoronary</keyword>
</DOC>